Review article: potassium‐competitive acid blockers for the treatment of acid‐related disorders
Authors:
Top Cited Papers
- 16 February 2021
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 53 (7) , 794-809
Abstract
Summary: Background: Potassium‐competitive acid blockers (P‐CABs) are a novel group of acid‐suppressing medicines for the management of acid‐related disorders.Aims: To review published clinical pharmacology studies and clinical trials of P‐CABs.Methods: We conducted a comprehensive literature search including Medline (PubMed), EMBASE, Web of Science and the Cochrane Library from inception until November 2020, for studies of the clinical pharmacology of P‐CABs and relevant clinical trials of those that are currently licensed or in development.Results: Most publications concerned vonoprazan, which forms the bulk of this review. It is currently licensed in some Asian and South American countries and is being developed for North America. In clinically relevant doses, P‐CABs have produced more rapid and profound suppression of intragastric acidity than proton pump inhibitors (PPIs). Vonoprazan was non‐inferior to lansoprazole in healing erosive oesophagitis (2 randomised controlled trials [RCTs] in 1137 subjects) and superior in maintaining remission (1 RCT; 607 subjects). In 2 RCTs (1120 total subjects), both vonoprazan and tegoprazan were non‐inferior to lansoprazole for healing peptic ulcers. Three RCTs and numerous non‐randomised studies have compared vonoprazan‐based and PPI‐based regimens forHelicobacter pyloriinfection; vonoprazan‐based triple or dual regimens have been highly effective.Conclusions: P‐CABs have some potential advantages over PPIs. To date, most research has been conducted in Asia; results of clinical trials that are underway in the United States and Europe are anticipated in 2021.Keywords
This publication has 98 references indexed in Scilit:
- Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signalingJournal of Clinical Biochemistry and Nutrition, 2012
- Nonsteroidal Antiinflammatory Drug-Related Injury to the Gastrointestinal Tract: Clinical Picture, Pathogenesis, and PreventionGastroenterology Clinics of North America, 2010
- Evaluation of basic, heterocyclic ring systems as templates for use as potassium competitive acid blockers (pCABs)Bioorganic & Medicinal Chemistry Letters, 2009
- Management of heartburn not responding to proton pump inhibitorsGut, 2009
- Evidence that the Degree and Duration of Acid Suppression are Related to Helicobacter pylori Eradication by Triple TherapyHelicobacter, 2007
- Smoking Increases the Treatment Failure for Helicobacter pylori EradicationThe American Journal of Medicine, 2006
- The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPaseAnnual Review of Pharmacology and Toxicology, 1995
- Appropriate Acid Suppression for the Management of Gastro-Oesophageal Reflux DiseaseDigestion, 1992
- The relationship between suppression of acidity and gastric ulcer healing ratesAlimentary Pharmacology & Therapeutics, 1990
- Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.Gut, 1987